2019
DOI: 10.1007/s00204-019-02495-6
|View full text |Cite
|
Sign up to set email alerts
|

Identification of novel agonists by high-throughput screening and molecular modelling of human constitutive androstane receptor isoform 3

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
15
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(18 citation statements)
references
References 53 publications
2
15
1
Order By: Relevance
“…It is likely that these in silico methods will not be discriminating enough to quickly and reliably detect and distinguish between all CAR agonists and inverse agonists, but they are valuable as supportive tools either for pre-selection before or mechanistic binding evaluations after the functional assays (e.g. Küblbeck et al, 2011aKüblbeck et al, , 2011bLynch et al, 2013;Keminer et al, 2019) that will be described below.…”
Section: Structural Features That Contribute To High Constitutive Act...mentioning
confidence: 99%
See 3 more Smart Citations
“…It is likely that these in silico methods will not be discriminating enough to quickly and reliably detect and distinguish between all CAR agonists and inverse agonists, but they are valuable as supportive tools either for pre-selection before or mechanistic binding evaluations after the functional assays (e.g. Küblbeck et al, 2011aKüblbeck et al, , 2011bLynch et al, 2013;Keminer et al, 2019) that will be described below.…”
Section: Structural Features That Contribute To High Constitutive Act...mentioning
confidence: 99%
“…The second approach relies on the use of natural (CAR3; Keminer et al, 2019;Skoda et al, 2020) or artificial CAR variants where the basal activity is reduced by addition of amino acids to the human (Chen et al, 2010;Imai et al, 2013;Kanno et al, 2010) or animal CAR LBDs (Omiecinski et al, 2011;Pinne et al, 2016). This approach carries the risk of affecting selectivity of the LBP (CAR2 or insertions near H12) or the CAR/RXR binding (CAR3 or insertion of single alanine instead of APYLT) that may affect the ligand-dependent changes in coactivator recruitment.…”
Section: Strategies In Identifying Car Modulatorsmentioning
confidence: 99%
See 2 more Smart Citations
“…The discovery of a hCAR activator suitable for clinical studies or one already used in pharmacotherapy would be a milestone in the characterization of hCAR as a molecular target in pharmacotherapy. Among the variety of compounds characterized as hCAR activators using in vitro high-throughput screenings, only a few compounds are on the market [7,14,15]. For instance, the routinely used pharmaceuticals diazepam and phenytoin have been described as hCAR activators in vitro, but only one solitary drug-to-drug interaction possibly connected with hCAR activation has been reported [16].…”
Section: Introductionmentioning
confidence: 99%